|
|||||
|
|
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice |
|
| Authors: | A. M. D. Watson J. Li C. Schumacher M. de Gasparo B. Feng M. C. Thomas T. J. Allen M. E. Cooper K. A. M. Jandeleit-Dahm |
| Affiliation: | (1) Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, 8008, VIC, Australia;(2) Novartis Pharma, Basel, Switzerland;(3) MG Consulting, Rossemaison, Switzerland |
| Abstract: | Aims/hypothesisThere is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular disease. This study aimed to assess the effects of the non-peptidergic endothelin receptor A (ETA) antagonist avosentan in a mouse model of accelerated diabetic nephropathy and atherosclerosis in comparison with the ACE inhibitor, quinapril. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |